(Q40529963)

English

Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation

scientific article published on January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

0 references

Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

0 references

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Sandra Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Laura Jakul

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Kathryn Sexton

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

10-19

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

21 January 2018

Are placebo run ins justified?

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

21 January 2018

Why sources of heterogeneity in meta-analysis should be investigated

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

21 January 2018

Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

21 January 2018

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice.

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A study comparing paroxetine placebo and imipramine in depressed patients

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo washout is not a meaningful part of antidepressant drug trials

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

Onset of response in relation to outcome in depressed outpatients with placebo and imipramine

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A Statistical Review of Controlled Trials of Imipramine and Placebo in the Treatment of Depressive Illnesses

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

The Oral Dose-Effect Relationship for Fluvoxamine: a Fixed-Dose Comparison Against Placebo in Depressed Outpatients

1 reference

https://api.crossref.org/works/10.1002%2FDA.10134

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.10134

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40529963&oldid=1900018703"